IPP Bureau
Bristol Myers Squibb’s mezigdomide cuts myeloma progression risk by 52%
By IPP Bureau - May 31, 2026
MeziKd delivered stronger response rates across multiple patient groups, including those receiving second- and third-line treatment and patients with higher-risk disease
AbbVie bags major European label expansion for VENCLYXTO in chronic lymphocytic leukemia
By IPP Bureau - May 31, 2026
The expanded indication is backed by data from the Phase 3 AMPLIFY and GLOW trials and the Phase 2 CAPTIVATE study,
Pfizer's LORBRENA delivers landmark seven-year survival results in advanced lung cancer trial
By IPP Bureau - May 30, 2026
The findings mark one of the longest progression-free survival outcomes ever reported in advanced lung cancer
Merck’s experimental cancer drug wins FDA breakthrough status in key lung cancer setting
By IPP Bureau - May 30, 2026
The designation marks the first Breakthrough Therapy recognition for calderasib and is backed by positive results from the Phase 1 KANDLELIT-001 clinical trial
Glenmark posts strong FY26 results with 27.5% revenue jump
By IPP Bureau - May 30, 2026
Lupin wins FDA nod for generic colonoscopy prep drug with first-to-file exclusivity
By IPP Bureau - May 30, 2026
Crucially, Lupin is the exclusive first-to-file applicant for this product and is eligible for 180-day generic drug exclusivity in the U.S. market
AstraZeneca reports mixed Phase III results for anselamimab in rare cardiac amyloidosis trial
By IPP Bureau - May 30, 2026
The programme evaluated anselamimab as a first-line add-on to standard plasma cell dyscrasia therapy in patients with advanced cardiac AL amyloidosis
FDA greenlights AstraZeneca’s Imfinzi combo in bladder cancer breakthrough
By IPP Bureau - May 30, 2026
The study tracked patients for more than five years (median 60.7 months), with protection against disease returning emerging in under four months and continuing long term
FDA delays AstraZeneca decision on camizestrant as regulators seek more data
By IPP Bureau - May 30, 2026
The filing is backed by results from the pivotal SERENA-6 Phase III trial
Lupin secures FDA nod for generic Sutab tablets with 180-day exclusivity
By IPP Bureau - May 30, 2026
The approved product is the generic equivalent of Sutab® Tablets developed by Azurity Pharmaceuticals
Fermenta Biotech reports 26% revenue growth in FY26
By IPP Bureau - May 30, 2026
HPS felicitates Padma Shri awardee Dr. G. Venkat Rao for outstanding work in healthcare
By IPP Bureau - May 30, 2026
The Hyderabad Public School Society celebrates Dr Rao’s journey from HPS Ramanthapur to becoming one of India's leading medical professionals
Alkem Labs posts highest-ever EBITDA in FY26; Q4 revenue rises 14.6%
By IPP Bureau - May 29, 2026
Strong domestic and international growth, improving product mix, and operational efficiencies drive margin expansion despite exceptional charges impacting quarterly profit
Supreme Court declares right to trauma care part of Article 21 in landmark judgement
By IPP Bureau - May 29, 2026
The ruling comes against the backdrop of a mounting trauma burden in India, where nearly 4.67 lakh accidental deaths occur annually
